NexEos Bio detects, diagnoses, treats, and life-long manages patients living with chronic, eosinophil-related inflammatory diseases.
NexEos Bio has raised $3.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2026.
NexEos Bio is headquartered in Pottstown, United States.
NexEos Bio detects, diagnoses, treats, and life-long manages patients living with chronic, eosinophil-related inflammatory diseases.
NexEos Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NexEos Bio — Funding & Investors." VCBacked, February 17, 2026, https://www.vcbacked.co/company/nexeos-bio. Accessed August 6, 2026.
VCBacked. (2026). NexEos Bio — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/nexeos-bio
{{cite web |title=NexEos Bio — Funding & Investors |url=https://www.vcbacked.co/company/nexeos-bio |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated